A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
PHASE2
Non-small cell lung cancer (NSCLC) is a common type of lung cancer where ab...
Status
Recruiting
Location
Ironwood Cancer and Research Centers - Chandler II /ID# 275443